ES2152989T3 - Ligandos para los receptores de gastrina y cck. - Google Patents

Ligandos para los receptores de gastrina y cck.

Info

Publication number
ES2152989T3
ES2152989T3 ES94922318T ES94922318T ES2152989T3 ES 2152989 T3 ES2152989 T3 ES 2152989T3 ES 94922318 T ES94922318 T ES 94922318T ES 94922318 T ES94922318 T ES 94922318T ES 2152989 T3 ES2152989 T3 ES 2152989T3
Authority
ES
Spain
Prior art keywords
sup
sub
gastrine
cck
receivers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94922318T
Other languages
English (en)
Inventor
Sarkis Barret Kalindjian
Katherine Isobel Mary Steel
Michael John Pether
Jonathan Michael Richar Davies
Caroline Minli Rachel Low
Martin Lyn Hudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
James Black Foundation Ltd
Original Assignee
James Black Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939316608A external-priority patent/GB9316608D0/en
Application filed by James Black Foundation Ltd filed Critical James Black Foundation Ltd
Application granted granted Critical
Publication of ES2152989T3 publication Critical patent/ES2152989T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)

Abstract

LOS COMPUESTOS DE LA FORMULA (IA), (IB) O (IC), EN DONDE A REPRESENTA UN GRUPO QUE TIENE DOS ANILLOS FUSIONADOS, O UN GRUPO DE LA FORMULA (ID), R{SUP,1}{SUB,(M REPRESENTA HASTA 6 SUSTITUYENTES, K REPRESENTA -O-, -S-, -CH{SUB,2}, -N(R{SUP,2})O -N(COR{SUP,2})-, EN DONDE R{SUP,2} ES H O ALQUILO C{SUB,1} A C{SUB,3}, W ES UN GRUPO CARBONILO, SULFONILO O SULFINILO, Y X ES UN GRUPO CARBONILO, SULFONILO O SULFINILO, CON LA CONDICION DE QUE AL MENOS UNO DE ENTRE W Y X CONTENGA CARBONILO, Y Y Z REPRESENTAN LO INDICADO EN LA DESCRIPCION Y SUS SALES FARMACEUTICAMENTE ACEPTABLES SON LIGANDOS EN LOS RECEPTORES DE CCK Y/O DE GASTRINA.
ES94922318T 1993-08-10 1994-08-09 Ligandos para los receptores de gastrina y cck. Expired - Lifetime ES2152989T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939316608A GB9316608D0 (en) 1993-08-10 1993-08-10 Gastrin and cck receptor ligands
GB9410688A GB9410688D0 (en) 1993-08-10 1994-05-27 Gastrin and CCK receptor ligands

Publications (1)

Publication Number Publication Date
ES2152989T3 true ES2152989T3 (es) 2001-02-16

Family

ID=26303354

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94922318T Expired - Lifetime ES2152989T3 (es) 1993-08-10 1994-08-09 Ligandos para los receptores de gastrina y cck.

Country Status (18)

Country Link
US (1) US5919829A (es)
EP (1) EP0720601B1 (es)
JP (1) JP3980052B2 (es)
AT (1) ATE197146T1 (es)
AU (1) AU682051B2 (es)
CA (1) CA2167154A1 (es)
DE (1) DE69426205T2 (es)
DK (1) DK0720601T3 (es)
ES (1) ES2152989T3 (es)
FI (1) FI115050B (es)
GR (1) GR3035100T3 (es)
HU (1) HU222178B1 (es)
NO (1) NO306945B1 (es)
NZ (1) NZ269827A (es)
PL (1) PL181782B1 (es)
PT (1) PT720601E (es)
SG (1) SG52229A1 (es)
WO (1) WO1995004720A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032949A1 (en) * 1994-05-27 1995-12-07 James Black Foundation Limited Gastrin and cck antagonists
WO1998002419A1 (en) * 1996-07-12 1998-01-22 Chugai Seiyaku Kabushiki Kaisha Cancer cell proliferation inhibitors
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
ES2194209T3 (es) * 1996-07-22 2003-11-16 Monsanto Co Inhibidores de metaloproteasa de tiol sulfona.
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JP2002515488A (ja) * 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
CN1325385A (zh) 1998-11-09 2001-12-05 詹姆斯·布莱克基金有限公司 胃泌素和缩胆囊素受体配体
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
CN1147483C (zh) 1999-04-09 2004-04-28 阿斯特拉曾尼卡有限公司 金刚烷衍生物
WO2000063171A1 (en) 1999-04-20 2000-10-26 Meiji Seika Kaisha, Ltd. Tricyclic compounds
US7045287B2 (en) * 1999-07-20 2006-05-16 Agilent Technologies, Inc. Method for contacting fluid components with moieties on a surface
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
MXPA04010555A (es) 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SI1651621T1 (sl) * 2003-08-08 2008-12-31 Janssen Pharmaceutica Nv 2-(kinoksalin-5-ilsulfonilamino)-benzamidne spojine kot modulatorji CCK2
WO2006040329A1 (en) * 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
JPWO2006095922A1 (ja) * 2005-03-10 2008-08-21 京都薬品工業株式会社 テトラヒドロイソキノリン化合物およびその医薬用途
BRPI0618051A2 (pt) * 2005-11-01 2011-08-16 Transtech Pharma Inc uso farmacêutico de amidas substituìdas
KR20080076916A (ko) * 2005-11-01 2008-08-20 트랜스테크 파르마, 인크. 치환된 아미드의 약학적 사용
EP2007722A1 (en) * 2006-03-21 2008-12-31 High Point Pharmaceuticals, LLC Adamantane derivatives for the treatment of the metabolic syndrome
KR20090014347A (ko) 2006-04-07 2009-02-10 하이 포인트 파마슈티칼스, 엘엘씨 11β-히드록시스테로이드 탈수소효소 타입 1 활성 화합물
EP2038255A2 (en) * 2006-06-16 2009-03-25 High Point Pharmaceuticals, LLC Pharmaceutical use of substituted piperidine carboxamides
EP1878721A1 (en) * 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
US8048908B2 (en) * 2006-07-13 2011-11-01 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
JP2010519239A (ja) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害因子としてのｎ−アドマンチルベンザミド
WO2008101907A2 (en) * 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
EP2125704A1 (en) * 2007-02-23 2009-12-02 High Point Pharmaceuticals, LLC N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
ZA200904916B (en) 2007-02-23 2010-09-29 High Point Pharmaceuticals Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
CN101652359A (zh) * 2007-03-09 2010-02-17 高点制药有限责任公司 作为羟类固醇脱氢酶抑制剂的吲哚-和苯并咪唑酰胺类
BRPI0809106A2 (pt) 2007-03-22 2014-08-26 Astrazeneca Ab Derivados de quinolina para o tratamento de doenças inflamatórias
EP2141990A4 (en) * 2007-03-28 2011-07-06 High Point Pharmaceuticals Llc ACTIVE COMPOUNDS ON 11BETA-HSD1
CN101677562A (zh) * 2007-04-11 2010-03-24 高点制药有限责任公司 新化合物
JP2010526777A (ja) * 2007-04-24 2010-08-05 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換アミドの医薬用途
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
JP2012509879A (ja) * 2008-11-21 2012-04-26 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー アダマンチルベンズアミド化合物
CN114369040B (zh) * 2022-03-21 2022-07-05 广州同隽医药科技有限公司 2-（3-（对羟苯基）-丙酰胺基）-苯甲酸葡糖胺盐及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343804A (en) * 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
US4757151A (en) * 1985-11-14 1988-07-12 Warner-Lambert Company 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl]
US4814463A (en) * 1985-12-31 1989-03-21 Biomeasure, Inc. CCK antagonists
CA1326108C (en) * 1988-04-12 1994-01-11 Sun Hyuk Kim Cck antagonists
KR920701162A (ko) * 1990-03-28 1992-08-11 오츠카 아끼히코 퀴놀린 유도체, 당해 유도체를 함유하는 항궤양제 및 당해 유도체의 제조방법
US5217957A (en) * 1991-08-20 1993-06-08 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression
GB9206757D0 (en) * 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
US5795907A (en) * 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands

Also Published As

Publication number Publication date
PL312960A1 (en) 1996-05-27
PL181782B1 (pl) 2001-09-28
DK0720601T3 (da) 2000-11-20
AU682051B2 (en) 1997-09-18
HU222178B1 (hu) 2003-04-28
FI960572A0 (fi) 1996-02-07
HU9600070D0 (en) 1996-03-28
FI115050B (fi) 2005-02-28
JPH09502430A (ja) 1997-03-11
PT720601E (pt) 2001-02-28
NZ269827A (en) 1996-10-28
EP0720601B1 (en) 2000-10-25
FI960572A7 (fi) 1996-02-07
EP0720601A1 (en) 1996-07-10
SG52229A1 (en) 1998-09-28
NO960488L (no) 1996-03-15
HUT75301A (en) 1997-05-28
CA2167154A1 (en) 1995-02-16
JP3980052B2 (ja) 2007-09-19
DE69426205D1 (de) 2000-11-30
DE69426205T2 (de) 2001-03-08
WO1995004720A3 (en) 1995-08-03
AU7347894A (en) 1995-02-28
US5919829A (en) 1999-07-06
ATE197146T1 (de) 2000-11-15
WO1995004720A2 (en) 1995-02-16
NO960488D0 (no) 1996-02-06
GR3035100T3 (en) 2001-03-30
NO306945B1 (no) 2000-01-17

Similar Documents

Publication Publication Date Title
ES2152989T3 (es) Ligandos para los receptores de gastrina y cck.
ES2000216A6 (es) Procedimiento para preparar un polipeptido purificado que tiene propiedades inhibidoras de la coagulacion de la sangre.
GEP20074251B (en) N-oxycarbonyl substituted 5'- deoxy-5-fluorocytidines
ES2062395T3 (es) Nuevos compuestos de bencimidazol y su uso.
IS4166A (is) Aðferð til að framleiða nýjar peptíðafleiður sem eru þrombíntálmar
ATE106401T1 (de) Benzodiazepin-analoge.
ES2063036T3 (es) Compuestos (aralquil-sustituido) heterociclicos.
ES2148476T3 (es) Derivados de azabicicloalcano n-substituidos como neurolepticos asf.
DE69211733D1 (de) Gasgenerator
ES8707974A1 (es) Procedimiento para la obtencion de un peptido
ES2134777T3 (es) Nuevos compuestos de sulfonilo.
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
SE8702550D0 (sv) Cysteinproteashemmare
NO991834L (no) Bifenylderivater substituert med et aromatisk eller heteroaromatisk radikal, og farmas°ytiske og kosmetiske sammensetninger inneholdende disse
ATE251624T1 (de) Granulatimide-derivate zur behandlung von krebs
ES2059416T3 (es) 1,4-dihidropiridina-enantiomeros.
ES2043863T3 (es) Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
DE69226770D1 (de) Gasgenerator
DK92388D0 (da) Diorganopolysiloxangruppeholdige disubstituerede n,n'-bis-maleimider samt fremgangsmaade til fremstilling deraf
IT220724Z2 (it) Equipaggiamento chirurgico per operazioni di tracheotomia
ES2182090T3 (es) Nuevos derivados de pirrol.
ES2126155T3 (es) Nuevos compuestos aminoesteroidales que contienen uretano.
ES2061478T3 (es) Derivados de teofilin-metil-ditiolano y teofilin-metil-ditianilo, un metodo para su preparacion, y composiciones farmaceuticas que los contienen.
PA8513301A1 (es) Inhibidor del intercambiador de sodio-hidrògeno de tipo 1

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 720601

Country of ref document: ES